Standout Papers

NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer 2024 202639
  1. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer (2024)
    Federico Nichetti, Chiara Pircher et al. JAMA Network Open

Immediate Impact

62 standout
Sub-graph 1 of 22

Citing Papers

Pancreatic cancer
2025 Standout
Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy
2025 Standout

Works of Federica Morano being referenced

Updated results and subgroup analysis by presence of liver metastases of a phase I/II study of the EP4 antagonist vorbipiprant with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC).
2024
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
2024 Standout

Author Peers

Author Last Decade Papers Cites
Federica Morano 475 335 422 76 1.1k
Bala Başak Öven Ustaalıoğlu 509 424 355 84 1.1k
Cosimo Sacco 516 381 210 59 1.1k
SP Stenning 383 517 454 39 1.3k
Mesut Şeker 598 473 399 97 1.3k
Peter Kozuch 541 256 244 41 1.0k
Eun‐Kee Song 615 371 273 77 1.3k
Gun Min Kim 753 521 210 90 1.3k
Ebbe Lindegaard Madsen 287 308 540 34 907
Fabio Carboni 412 517 561 80 1.0k
M. R. Moore 417 279 223 38 1.1k

All Works

Loading papers...

Rankless by CCL
2026